Background-Safety data on percutaneous left atrial appendage closure arises from centers with considerable expertise in the procedure or from clinical trial, which might not be reproducible in clinical practice. We sought to estimate the frequency and predictors of adverse outcomes and costs of percutaneous left atrial appendage closure procedure in the US. Methods and Results-The data were obtained from the Nationwide Inpatient Sample from the years 2006 to 2010. The Nationwide Inpatient Sample is the largest all-payer inpatient data set in the US. Complications were calculated using patient safety indicators and International Classification of Diseases-Ninth Revision, Clinical Modification codes. Annual hospital volume was calculated using unique hospital identifiers. Weights provided by the Nationwide Inpatient Sample were used to generate national estimates. A total of 268 (weighted=1288) procedures were analyzed. The overall composite rate of mortality or any adverse event was 24.3% (65), with 3.4% patients required open cardiac surgery after procedure. Average length of stay was 4.61±1.05 days and cost of care was 26 024±34 651. Annual hospital procedural volume was significantly associated with reduced complications and mortality (every unit increase: odds ratio, 0.89; 95% confidence interval, 0.85-0.94; P<0.001), decrease in length of stay (every unit increase: hazard ratio, 0.95; 95% confidence interval, 0.92-0.98; P<0.001) and cost of care (every unit increase: hazard ratio, 0.96; 95% confidence interval, 0.93-0.98; P<0.001). Conclusions-Our study demonstrates that the frequency of inhospital adverse outcomes associated with percutaneous left atrial appendage closure is higher in the real-world population than in clinical trials. We also demonstrate that higher annual hospital volume is associated with safer procedures, with lower length of stay and cost. (Circ Arrhythm Electrophysiol. 2015;8:42-48.
L eft atrial appendage (LAA) is the most common source (>90%) of cardioembolic stroke in atrial fibrillation (AF). 1 Although most common treatment for stroke prevention is systemic anticoagulation, for selected subgroup of AF patients who have contraindication or difficulty in medication adherence, nonpharmacological approaches for LAA closure have been developed over the years. 2, 3 Watchman system, Fibrillation) and all other drug-versus-device evaluations, there is a higher initial rate of adverse events in patients undergoing device implantation. 7 However, real-time imaging guidance has potentially improved the safety and efficacy of these procedures compared with fluoroscopy. Transesophageal echocardiography (TEE) is typically used to guide percutaneous LAA closure procedures and to perform septal puncture. One alternative to TEE is the use of intracardiac echocardiography (ICE), which has proven to be useful in a variety of interventional procedures. 8 The majority of data on the safety of percutaneous LAA closure comes from selected centers and operators with considerable expertise in the procedure. Outcomes attained in the context of clinical trials might not be reproducible in real-world clinical practice. In light of these observations, the main objective of this study was to estimate the frequency and predictors of inhospital complications, utilization, and procedural costs in the real-world sample of patients undergoing percutaneous closure of the LAA in the United States.
Methods
The data were obtained from the Nationwide Inpatient Sample (NIS) 9 of the Healthcare Cost and Utilization Project from 2006 to 2010. International Classification of Diseases-Ninth Revision, Clinical Modification (ICD-9-CM) procedure code of 37.90 for insertion of LAA device was used to select study patients. It is the largest allpayer inpatient data set in the United States. The 2010 NIS contains all discharge data from 1051 hospitals located in 45 states, approximating a 20% stratified sample of all US community hospitals.
Each NIS database entry contains information on demographics, including age, sex, race, insurance status, primary and secondary procedures, hospitalization outcome, total cost, and length of stay. Results of this database have been shown to correlate well with other hospitalization discharge databases in the United States. 10 It has also been used to explain trends in other acute medical and surgical conditions. 11 Annual data quality assessments of the NIS are performed, which guarantee the internal validity of the database. Furthermore, comparisons against the following data sources strengthen the external validity of the NIS: the American Hospital Association Annual Survey Database, the National Hospital Discharge Survey from the National Center for Health Statistics, and the MedPAR inpatient data from the Centers for Medicare and Medicaid Services. 12
Definition of Variables
We used NIS variables to identify patient age, sex, and race. We defined severity of comorbid conditions using Deyo modification of Charlson Comorbidity Index, which contains 17 comorbid conditions with differential weights ( Table I in the Data Supplement). 13 The score ranges from 0 to 33, with higher scores corresponding to a greater burden of comorbid diseases. Facilities were considered to be teaching hospitals 14 if they had an American Medical Association-approved residency program, were members of the Council of Teaching Hospitals, or had a fulltime equivalent of interns and residents to patient ratio of ≥0.25. Hospital location (rural versus urban) and size (small versus medium versus large) were also analyzed. 15 Annual hospital volume was determined on a year-to-year basis, using the unique hospital identification number to calculate the total number of procedures performed by a particular institution in a given year. For further analysis, annual hospital volume was divided into tertiles: first tertile <3, second tertile 3 to 18, third tertile >18 LAA closure procedures per year.
Outcomes
We investigated the acute inhospital complications associated with LAA closure. Procedural complications were divided into the following broad categories: vascular complications, cardiac complications, cardiac complications necessitating open-heart surgery, respiratory complications, neurological complications, and renal and metabolic complications. Complications were calculated using patient safety indicators, 16, 17 which are based on the ICD-9-CM and Medicare Severity Diagnosis-Related Groups (MS-DRG). Separate ICD-9-CM codes were used to calculate procedural complications not included by patient safety indicator ( Table II in the Data Supplement). This methodology has been used in earlier studies. 18 
Statistical Analysis
We used the weights provided by the NIS to generate national estimates of the admissions during each year. χ 2 test and rank-sum test were used to compare categorical and continuous variables, respectively. Hierarchical mixed-effects regression models were generated to identify the multivariable predictors of postprocedural complications, length of stay, and procedural cost. Log of LOS and procedural cost were used as they were not normally distributed. Two-level hierarchical models (with patient-level factors nested within hospitallevel factors) were created with the unique hospital identification number incorporated as random effects within the model. The following variables were included in all multivariable models: hospitallevel variables such as hospital region (Northeast, South, West, and Midwest), teaching versus nonteaching hospital, and annual hospital procedural volume and patient-level variables such as age, sex, Deyo modification of Charlson Comorbidity Index, primary payer (with Medicare/Medicaid considered as referent), weekday versus weekend admission, and ICE use during procedure. Hospital ID was incorporated into the model as a random effect to account for the effect of hospital clustering. Separate multivariable models with annual hospital volume as continuous variable and then as a categorical variable (using hospital volume tertiles) were used to observe any changes in strength of association of predictors after splitting the data in tertiles ( Table III in the Data Supplement) All statistical tests were 2-sided. We used Stata IC 11.0 (Stata-Corp, College Station, TX) for all analyses, and P values of <0.05 were considered significant.
WHAT IS KNOWN
• Nonpharmacological strategies for stroke prevention using percutaneous closure of the left atrial appendage in nonvalvular atrial fibrillation have advanced significantly during the past decade.
• Randomized studies comparing the Watchman device versus warfarin have shown noninferiority for stroke prevention in patients with atrial fibrillation with comparable safety profiles.
• The majority of safety and clinical outcome data for these devices comes from clinical trial rather than real-world experience.
WHAT THE STUDY ADDS
• We analyzed a total of 1288 procedures from year 2006 to 2010 across the United States and we found that the frequency of inhospital adverse outcomes associated with percutaneous left atrial appendage closure is slightly higher (24.3%) in the real-world population than in clinical trials.
• However, inhospital mortality (2.3%) was similar to previous reports.
• The procedure-related mortality, complication rates, length of hospitalization, and cost are significantly associated with annual hospital volume.
Results

Patient and Procedural Demographics
Baseline characteristics of the study population are summarized in Table 1 . During the study period (2006-2010), 268 percutaneous LAA closure procedures (weighted to entire US popula-tion=1288) were performed in the United States. The majority of the patients were older (average age, 70±12 years), white men (71%). Hypertension (68%) and diabetes mellitus (22%) were the 2 most common comorbidities. Most of these cases were performed at large (72.5%) teaching hospitals (59%), with a mean cost of $26 024 per procedure and an average LOS of 4.61±1.05 days. The majority of patients (89.2%) were discharged home after the procedure, with only 8.5% requiring disposition to a different healthcare facility. ICE was used in 6.6% cases; however, there was no standardization as to how was ICE used during the LAA closure. Distinction between transthoracic echocardiography and transesophageal echocardiography was not possible because of same ICD-9-CM code.
Complications
The overall adverse event rate was 24.3% and the inhospital mortality rate was 2.3%. Vascular complications occurred in 4.5% of the cases, mostly secondary to postoperative hemorrhage requiring blood products (4.1%).
Other vascular complications such as injury to blood *Race was missing in 16.5% of the patient population. †Charlson Comorbidity Index was calculated using ICD-9 codes. 13 ‡This represents a quartile classification of the estimated median household income of residents in the patient's ZIP code. These values are derived from ZIP code demographic data obtained from Claritas. The quartiles are identified by values of 1 to 4, indicating the poorest to wealthiest populations. Because these estimates are updated annually, the value ranges vary by year (http:// www.hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nisnote.jsp).
§Admission type was missing in 27.8% of the population.
║For each year, cost was adjusted for inflation according to the reference 2010 cost. Cost was missing in 5.2% of cases.
¶Periprocedural complications were coded as using PSI indicator codes and ICD-9 diagnosis codes, for complications not coded by a PSI indicator. Postoperative strokes or transient ischemic attacks were reported in 3.3% of cases, whereas renal and metabolic complications, such as renal failure requiring dialysis, postoperative deep vein thrombosis or pulmonary embolism and postoperative infectious complications, occurred less frequently. Respiratory complications (respiratory failure and iatrogenic complications) were reported in 5.7% of the cases ( Table 2 ).
Predictors of Mortality and Complications
A statistically significant reduction in composite rate of complication and mortality was apparent for every unit increase in annual hospital LAA closure volume (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.85-0.94; P<0.001; Table 3 ). Significant reduction in mortality and complication rate was identified for the third tertile of annual hospital volume as well, which corresponds to ≥18 LAA closures per year (46% in first tertile versus 3% in third tertile; P<0.001; Figure 1 ). Similarly, a higher burden of baseline comorbidities as represented by the Charlson Comorbidity Index ≥2 (HR, 3.65; 95% CI, 1.50-8.89; P<0.001) was associated with worse postprocedural outcomes.
Determinants of Hospitalization Cost and Length of Stay
We found that annual hospital volume was significantly associated with hospitalization cost and LOS (Tables 4 and 5 ). Every unit increase in annual procedural volume was associated with reduced length of stay (HR, 0.95; 95% CI, 0.92-0.98; P<0.001) and reduced hospitalization cost (HR, 0.96; 95% CI, 0.93-0.98; P<0.001). Similar results were seen in the LOS and hospitalization cost model with highest annual hospital volume tertiles compared with the first tertile ( Table  III in the Data Supplement). ICE use during LAA closure was associated with reduced LOS (HR, 0.44; 95% CI, 0.30-0.66; P<0.001) without any significant impact on hospitalization costs (Figure 2 ).
Discussion
Using the largest national hospitalization database in the United States, we report herein the contemporary experience of the LAA closure procedure in a 5-year period (2006-2010). The main findings of our study are (1) the overall complication rate associated with percutaneous LAA closure is slightly higher in the real-world population than in clinical trials; (2) the procedure-related mortality, complication rates, length of hospitalization, and cost are significantly influenced by annual hospital volume; and (3) the use of ICE guidance shows trend toward lower LOS. 4 †Hemorrhage requiring transfusion was defined as any patient having a postoperative hemorrhage along with a transfusion. ‡Infectious complications were defined as a composite of postoperative sepsis, septic shock, or catheter-related infection. Overall, the mortality rate is lower in our study (2.3%) compared with previous studies. The mortality rate in PROTECT-AF was 3.2% in the arm undergoing Watchman implantation and in the most recent observational study with the ACP it was 5.8%. Most of the deaths in PROTECT-AF and ACP occurred during the follow-up, so they were most likely unrelated to device implantation. 5 In our study, the overall adverse event rate was 24.3%, which is higher than that reported in previously published studies. We have included a more comprehensive and a broader range of complications (including infections, DVT, pressure ulcer, and renal failure) in our study, which could explain this higher complication rate. Also, patient safety indicators, which were used to calculate complications, are well validated and used by the Agency for Healthcare Research and Quality (AHRQ) to compare the rate of avoidable adverse events in any 2 hospitals. 19 The total rate of cardiac complications (12.4%), including pericardial effusion and cardiac tamponade, in our analysis seems higher than previously reported; however, the rate of pericardiocentesis and open-heart surgery was comparatively lower. Early experience with the Watchman device revealed a total of 3.8% of serious pericardial effusions. However, the incidence of periprocedural pericardial effusions was only 1.9% with the ACP device. 5 The incidence of periprocedural neurological events, including stroke and transient ischemic attack, in our analysis is higher than previously reported. It compares with a total of 0.9% in PROTECT-AF who sustained a stroke during the procedure, whereas no procedure-related strokes have been observed in the Continued Access Protocol (CAP) registry. 7 Similarly, no periprocedural strokes were reported with the most recent data on ACP implantation. 5 Strokes related to the procedure are typically linked with sheath mismanagement (air embolism or inadequate flushing). Data from the CAP registry indicate that, with experience, it is possible to implant these devices with minimal risk of a procedure-related stroke.
The positive impact of increasing hospital volume on outcomes was substantiated in our analysis. It was most pronounced within the highest tertile, that is, for those institutions that performed ≥18 percutaneous LAA closures per year. This subgroup was associated with fewer complications and, not surprisingly, reduced hospitalization length and lower costs. As per Reddy et al, 7 the rate of major complication (bleeding, stroke, pericardial effusion, and device embolism) in PRTOECT-AF trial and CAP registry has been 7.7% and 3.7%, respectively. Hospitals with annual hospital volume ≥18 (highest tertile of annual hospital volume) showed overall complication rate of 3%, which is comparable with late PROTECT-AF. These findings also agree with the recently published CAP registry that demonstrated a 52% reduction in the safety event rate with increased operator experience. Given the ever-increasing economic burden of healthcare spending in the US, this finding suggests that perhaps percutaneous LAA closure, like other complex and highly technical procedures, should be performed only by centers and operators that can maintain an acceptable volume threshold.
It should be noted as well that reporting of various clinical trial and availability of lariat devices outside the clinical trials may have caused variable utilization of individual devices during our study period. Hypothetically, this could have modified the outcomes, given that device like lariat requires a transseptal puncture and a percutaneous epicardial access which add a different set of complications. Unfortunately, we were not able to differentiate between various devices because of single ICD-9 code. Thus, we could not assess the occurrence of complications associated with 1 particular device rather than another.
Most centers perform these procedures under TEE guidance, because fluoroscopy alone is not ideal, given that it may not be possible to rule out the presence of LAA thrombus, to accurately measure the LAA ostium in multiple dimensions, or to confirm the satisfactory positioning of the occlusion device. In our study, ICE was associated with a trend toward a significantly shorter LOS. However, the relatively smaller sample size of ICE procedures in our study limits any significant conclusion on postprocedural outcomes. Nonetheless, there have been selected cases outside clinical trials in which the device has been placed with the use of fluoroscopy plus ICE. 20 Our findings suggest that ICE might be a reasonable alternative in the future, The development of multiplanar or 3-dimensional ICE probes might make it possible to routinely implant the device without TEE. But for now, it should be emphasized that there is no well-studied large clinical experience with device implantation without TEE guidance; thus, our findings should be confirmed prospectively.
Limitations
Our study has several limitations. First, studies based on administrative databases are susceptible to errors related to coding. Second, we could not eliminate the effect of unmeasured confounders that might have contributed to the reporting of adverse effects. Third, the administrative data used in this analysis lack the detail that is available in trials and registries. Procedural details (fluoroscopy time, transseptal technique), physician characteristics (interventionalist versus electrophysiologist), full assessment of patients comorbidities (including outpatient diagnoses, paroxysmal versus persistent AF, or calculation of CHADS2 score) were unavailable for the analysis. We could not obtain reliable data pertaining to individual operator volume. Fourth, we had access to inhospital outcomes only; since our analysis does not have any data pertaining to clinical follow-up, some of the complications that appear after device implantation (dislodgement, device-associated thrombus, incomplete LAA closure) are not reported. However, most safety events in the CAP registry occurred perioperatively. Fifth, because of same ICD-9-CM code for TEE and TTE as well as the absence of ICD-9-CM code for general anesthesia, it was difficult to accurately report the rate of TEE use in our cohort. Sixth, operator experience with ICE or TEE was not available because of limitation of database and was not taken into account during this analysis. Finally, the diagnostic codes for all devices including Watchman, ACP, among them. All these limitations are counterbalanced by the fact that analysis was done in a large sample of patients, representing a real-world practice that is not subjected to the intense screening and monitoring that occur in the context of clinical trials.
In conclusion, our study demonstrates that the frequency of inhospital adverse outcomes associated with percutaneous LAA closure is slightly higher in the real-world population than in clinical trials. The procedure-related mortality, complication rates, length of hospitalization, and cost are significantly associated with annual hospital volume. Although the use of ICE was associated with shorter LOS, this result needs confirmation in larger study cohorts.
